Performance of STANDARD™ M10 SARS-CoV-2 Assay for the Diagnosis of COVID-19 from a Nasopharyngeal Swab
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The STANDARD™ M10 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) assay (M10 assay) (SD Biosensor Inc., Suwon, Korea) is a rapid, fully-automated, cartridge-type molecular diagnostic assay that detects SARS-CoV-2 RNA using primers and probes for each target gene (ORF1ab gene, E gene). This study evaluated its performance by assessing its concordance with the approved SARS-CoV-2 real-time PCR assay. Tests were performed on 80 nasopharyngeal samples. The sensitivity and specificity of the M10 assay were 100%. The M10 assay effectively diagnosed SARS-CoV-2 infection, and it was comparable to the approved SARS-CoV-2 real-time PCR assay. It is a viable point-of-care test due to its short turnaround time.
Abstract
The STANDARD™ M10 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) assay (M10 assay) (SD Biosensor Inc., Suwon, Korea) is a rapid, fully-automated, cartridge-type molecular diagnostic assay that detects SARS-CoV-2 RNA using primers and probes for each target gene (ORF1ab gene, E gene). This study evaluated its performance by assessing its concordance with the approved SARS-CoV-2 real-time PCR assay. Tests were performed on 80 nasopharyngeal samples. The sensitivity and specificity of the M10 assay were 100%. The M10 assay effectively diagnosed SARS-CoV-2 infection, and it was comparable to the approved SARS-CoV-2 real-time PCR assay. It is a viable point-of-care test due to its short turnaround time.
참고문헌 (10)
- Ki Ho Hong, "Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea", Annals of Laboratory Medicine, 40(5), pp.351~360 (2020), 대한진단검사의학회[DOI]
- Oh Sang-Min, "Clinical Application of the Standard Q COVID-19 Ag Test for the Detection of SARS-CoV-2 Infection", Journal of Korean Medical Science, 36(14), pp.1~5 (2021), 대한의학회[DOI]
- Turcato G, "Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department : a preliminary report", J Infect, 82, pp.e14~e16 (2021)
- Pray IW, "Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses-Wisconsin, September-October 2020", MMWR Morb Mortal Wkly Rep, 69, pp.1642~1647 (2021)
- Stevens B, "Comparison of a point-of-care assay and a high-complexity assay for detection of SARS-CoV-2 RNA", J Appl Lab Med, 5, pp.1307~1312 (2020)
- Goldenberger D, "Brief validation of the novel GeneXpert Xpress SARS-CoV-2PCR assay", J Virol Methods, 284, pp.113925~ (2020)
- Hur KH, "Evaluation of four commercial kits for SARS-CoV-2real-time reverse-transcription polymerase chain reaction approved by emergency-use-authorization in Korea", Front Med(Lausanne), 7, pp.521~ (2020)
- Buderer NM, "Statistical methodology : I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity", Acad Emerg Med, 3, pp.895~900 (1996)
- Clopper CJ, "The use of confidence or fiducial limits illustrated in the case of the binomial", Biometrika, 26, pp.404~413 (1934)
- Basu A, "Performance of abbott ID now COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New York City academic institution", J Clin Microbiol, 58, pp.e01136~20 (2020)